Objective To investigate the basic pharmacodynamic properties of teicoplanin in vitro for Staphylococcus aureus, Staphylococcus epidermidis and Enterococcus faecium. Methods The following experiments were performed: (1) bacterial killing by teicoplanin at different concentrations; (2) bacterial killing by teicoplanin at 8 x MIC against the same strains with inocula of 5x10(3), 5x10(5) and 5x10(7) CFU/mL; (3) studies of the postantibiotic effect (PAE) and the postantibiotic sub-MIC effect (PASME) of teicoplanin; (4) studies of the killing by teicoplanin in an in vitro kinetic model following exposure to simulated human serum pharmacokinetic concentrations (6 mg/kg OD at steady state). Results Concentration-dependent killing was noted against...
Kazuaki Matsumoto,1 Erika Watanabe,1 Naoko Kanazawa,1 Tomohide Fukamizu,1 Akari Shigemi,1 Yuta Yokoy...
International audienceObjectives: To investigate the population pharmacokinetics of teicoplanin in p...
Teicoplanin was compared with vancomycin for the prophylaxis of experimental Enterococcus faecalis e...
ObjectiveTo investigate the basic pharmacodynamic properties of teicoplanin in vitro for Staphylococ...
The effect of protein binding on the activity of teicoplanin against Staphylococcus aureus was evalu...
Objectives: Pharmacokinetic/pharmacodynamic (PK/PD) analysis using murine infection models is a well...
The prophylactic and therapeutic activities of teicoplanin were evaluated in two different experimen...
Teicoplanin, 200-400 mg (3-6 mg/kg) daily iv or im, was used to treat 71 episodes of infection. The ...
Objectives: The overall study aim was to identify the relevant preclinical teicoplanin pharmacokinet...
Teicoplanin (0-2 g) or vancomycin (1 g) were infused over 3 and 50 min respectively to six male volu...
We adapted an in vitro pharmacodynamic model of infection to incorporate simulated endocardial veget...
The glycopeptide antibiotic teicoplanin belongs to the same group as vancomycin and ristocetin and i...
most common cause of nosocomial infections and, typically, gram-positive pathogens are involved. M...
The in vitro antibacterial activity of teicoplanin, a new glycopeptide antibiotic, previously named ...
The susceptibility to teicoplanin of 100 coagulase negative staphylococci, predominantly isolated fr...
Kazuaki Matsumoto,1 Erika Watanabe,1 Naoko Kanazawa,1 Tomohide Fukamizu,1 Akari Shigemi,1 Yuta Yokoy...
International audienceObjectives: To investigate the population pharmacokinetics of teicoplanin in p...
Teicoplanin was compared with vancomycin for the prophylaxis of experimental Enterococcus faecalis e...
ObjectiveTo investigate the basic pharmacodynamic properties of teicoplanin in vitro for Staphylococ...
The effect of protein binding on the activity of teicoplanin against Staphylococcus aureus was evalu...
Objectives: Pharmacokinetic/pharmacodynamic (PK/PD) analysis using murine infection models is a well...
The prophylactic and therapeutic activities of teicoplanin were evaluated in two different experimen...
Teicoplanin, 200-400 mg (3-6 mg/kg) daily iv or im, was used to treat 71 episodes of infection. The ...
Objectives: The overall study aim was to identify the relevant preclinical teicoplanin pharmacokinet...
Teicoplanin (0-2 g) or vancomycin (1 g) were infused over 3 and 50 min respectively to six male volu...
We adapted an in vitro pharmacodynamic model of infection to incorporate simulated endocardial veget...
The glycopeptide antibiotic teicoplanin belongs to the same group as vancomycin and ristocetin and i...
most common cause of nosocomial infections and, typically, gram-positive pathogens are involved. M...
The in vitro antibacterial activity of teicoplanin, a new glycopeptide antibiotic, previously named ...
The susceptibility to teicoplanin of 100 coagulase negative staphylococci, predominantly isolated fr...
Kazuaki Matsumoto,1 Erika Watanabe,1 Naoko Kanazawa,1 Tomohide Fukamizu,1 Akari Shigemi,1 Yuta Yokoy...
International audienceObjectives: To investigate the population pharmacokinetics of teicoplanin in p...
Teicoplanin was compared with vancomycin for the prophylaxis of experimental Enterococcus faecalis e...